Clinically, tumours with high BCL-2 expression show poor pathological responses to chemotherapy, and combinations of docetaxel with BCL-2 inhibitors, such as venetoclax, are under investigation in triple-negative breast cancer [96,97]. This evidence concerns the gene BCL2 and triple-negative breast carcinoma.